1. Bringhurst R, Demay MB, Kronenberg HM. Hormones
and disorders of mineral metabolism. In Kronenberg HM, Melmed S,
Polonsky KS, Larsen PR, eds. Williams Textbook of Endocrinology.
11th ed. Philadelphia: Saunders/Elsevier; 2008: 1203-1368.
2. Favus MJ, ed. Primer on the Metabolic Bone Diseases
and Disorders of Mineral Metabolism. 6th ed, Washington,
DC: American Society for Bone and Mineral Research; 2006:1-514.
3. Root AW. Disorders of calcium metabolism. Normal homeostasis.
In Sperling MA, ed. Pediatric Endocrinology. 3rd
ed. Philadelphia: Saunders/Elsevier; 2008:74-126.
4. Greer FR, Krebs NF. Optimizing bone health and calcium intakes
of infants, children, and adolescents.
Pediatrics.
2006;117:578-585.
[PubMed: 16452385]
5. Lanou AJ, Berkow SE, Barnard ND. Calcium, dairy products,
and bone health in children and young adults: a reevaluation of
the evidence.
Pediatrics. 2005;115:736-743.
[PubMed: 15741380]
6. Winzenberg TM, Shaw K, Fryer J, Jones G. Effects of calcium
supplementation on bone density in healthy children: meta-analysis
of randomised controlled trials.
BMJ. 2006;333:775-778.
[PubMed: 16980314]
7. Favus MJ, Bushinsky DA, Lemann J Jr. Regulation of calcium,
magnesium, and phosphate metabolism. In Favus MJ, ed. Primer
on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.
6th ed. Washington, DC: American Society for Bone and Mineral Research;
2006:76-83.
8. Hsu SC, Levine MA. Perinatal calcium metabolism: physiology
and pathophysiology.
Semin Neonatol. 2004;9:23-36.
[PubMed: 15013473]
9. Brown EM, Juppner H. Parathyroid hormone: synthesis, secretion,
and action. In Favus MJ, ed. Primer on the Metabolic Bone
Diseases and Disorders of Mineral Metabolism. 6th ed. Washington,
DC: American Society for Bone and Mineral Research; 2006:90-99.
10. Steddon SJ, Cunningham J. Calcimimetics and calcilytics—fooling
the calcium receptor.
Lancet. 2005;365:2237-2239.
[PubMed: 15978932]
11. White KE, Larsson TE, Econs MJ. The roles of specific genes
implicated as circulating factors in normal and disordered phosphate
homeostasis: frizzled related protein-4, matric extracellular phosphoglycoprotein,
and fibroblast growth factor 23.
Endocrine Reviews.
2006;27:221-241.
[PubMed: 16467171]
12. Kolek OI, Hines ER, Jones MD, et al. 1α,25-Dihydroxyvitamin
D3 upregulates FGF23 gene expression in bone: the final
link in a renal-gastrointestinal-skeletal axis that controls phosphate
transport. Am J Physiol Gastrointest Liver Physiol.
2005;289:G1036-G1042.
13. Masuyama R, Stockmans I, Torrekens S, et al. Vitamin D receptor
in chondrocytes promotes osteoclastogenesis and regulates FGF23
production in osteoblasts.
J Clin Invest. 2006;116:3150-3159.
[PubMed: 17099775]
14. Burnett SAM, Gunawardene SC, Bringhurst FR, et al. Regulation
of C-terminal and intact FGF-23 by dietary phosphate in men and
women.
J Bone Miner Res. 2006;21:1187-1196.
[PubMed: 16869716]
15. Jan de Beur SM. Tumor-induced osteomalacia. In Favus MJ,
ed. Primer on the Metabolic Bone Diseases and Disorders
of Mineral Metabolism. 6th ed. Washington, DC: American
Society for Bone and Mineral Research; 2006:345-351.
16. Broadus AE, Nissenson RA. Parathyroid hormone-related protein.
In Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism, 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:99-106.
17. Deftos LJ. Calcitonin. In Favus MJ, ed. Primer on
the Metabolic Bone Diseases and Disorders of Mineral Metabolism.
6th ed. Washington, DC: American Society for Bone and Mineral Research;
2006:115-117.
18. Holick MF, Garabedian M. Vitamin D photobiology, metabolism,
mechanism of action, and clinical application. In Favus MJ, ed. Primer
on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.
6th ed. Washington, DC: American Society for Bone and Mineral Research;
2006:106-114.
19. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative
of vitamin D insufficiency: implications for establishing a new
effective dietary intake recommendation for vitamin D.
J
Nutr. 2005;135:317-322.
[PubMed: 15671234]
20. Iyer P, Diamond FB Jr. Shedding light on hypovitaminosis
D and rickets.
Adv Pediatr. 2007;54:115-133.
[PubMed: 17918469]
21. Norman AW. Minireview: vitamin D receptor: new assignments
for an already busy receptor.
Endocrinology. 2006;147:5542-5548.
[PubMed: 16946007]
22. Cohen MM Jr. The new bone biology: pathologic, molecular,
and clinical studies. Am J Med Genet. 2006;140A:2646-2706.
23. Aubin JE, Lian JB, Stein GB. Bone formation: maturation
and functional activities of osteoblast lineage cells. In Favus
MJ, ed. Primer on the Metabolic Bone Diseases and Disorders
of Mineral Metabolism. 6th ed. Washington, DC: American
Society for Bone and Mineral Research; 2006:20-29.
24. Ott SM. Editorial: Sclerostin and Wnt signaling—the
pathway to bone strength.
J Clin Endocrinol Metab.
2005;90:6741-6743.
[PubMed: 16330810]
25. Bilezikian JP. Editorial: what’s good for the goose’s
skeleton is good for the gander’s skeleton.
J Clin
Endocrinol Metab. 2006;91:1223-1225.
[PubMed: 16601197]
26. Vanderschueren D, Venken K, Ophoff J, et al. Clinical review:
sex steroids and the periosteum—reconsidering the roles
of androgens and
estrogens in periosteal expansion.
J Clin
Endocrinol Metab. 2006;91:378-382.
[PubMed: 16303833]
27. Ross FP. Osteoclast biology and bone resorption. In Favus
MJ, ed. Primer on the Metabolic Bone Diseases and Disorders
of Mineral Metabolism. 6th ed. Washington, DC: American
Society for Bone and Mineral Research; 2006:30-35.
28. Robey PG, Boskey AL. Extracellular matrix and biomineralization
of bone. In Favus MJ, ed. Primer on the Metabolic Bone Diseases
and Disorders of Mineral Metabolism. 6th ed. Washington,
DC: American Society for Bone and Mineral Research; 2006:12-19.
29. Chavassieux P, Seeman E, Delmas PD. Insights into material
and structural basis of bone fragility from diseases associated
with fractures. How determinants of the biomechanical properties
of bone are compromised by disease.
Endocr Rev.
2007;28:151-164.
[PubMed: 17200084]
30. Rubin C, Rubin J. Biomechanics and mechanobiology of bone.
In Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:36-42.
31. Van der Eerden BCJ, Karperien M, Wit J. Systemic and local
regulation of the growth plate. Endocr Rev. 2003:24:782-801.
32. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like
growth factors, and the skeleton.
Endocr Rev. 2008;29:535-559.
[PubMed: 18436706]
33. Robson H, Siebler T, Shalet SM, Williams GR. Interactions
between GH, IGF-I, glucocorticoids, and thyroid hormones during
skeletal growth. Pediatr Res. 2003;52:137-147.
34. Wang Y, Nishida S, Sakata T, et al. Insulin-like growth
factor-I is essential for embryonic bone development.
Endocrinology.
2006;147:4753-4761.
[PubMed: 16857753]
35. Savage MO, Attie KM, David A, et al. Endocrine assessment,
molecular characterization and treatment of growth hormone insensitivity.
Nat
Clin Prac Endocrinol Metab. 2006;2:395-407.
[PubMed: 16932322]
36. Barnard JC, Williams AJ, Rabier B, et al. Thyroid hormones
regulate fibroblast growth factor receptor signaling during chondrogenesis.
Endocrinology.
2005;146:5568-5580.
[PubMed: 16150908]
37. Rauch F, Bailey DA, Baxter-Jones A, et al. The “muscle-bone
unit” during the pubertal growth spurt.
Bone.
2004;34:771-775.
[PubMed: 15121007]
38. Couse JF, Korach KS. Estrogen receptor null mice: what have
we learned and where will they lead us?
Endocr Rev.
1999;20:358-417.
[PubMed: 10368776]
39. Janicka A, Wren TAL, Sanchez MM, et al. Fat mass is not
beneficial to bone in adolescents and young adults.
J Clin
Endocrinol Metab. 2007;92:143-147.
[PubMed: 17047019]
40. Baldock PA, Allison S, McDonald MM, et al. Hypothalamic
regulation of cortical bone mass: opposing activity of Y2 receptor
and leptin pathways.
J Bone Miner Res. 2006;21:1600-1607.
[PubMed: 16995815]
41. Luo X-H, Guo L-J, Xie H, et al. Adiponectin stimulates RANKL
and inhibits OPG expression in human osteoblasts through the MAPK
signaling pathway.
J Bone Miner Res. 2006;21:1648-1656.
[PubMed: 16995820]
42. Rauch F. Watching bones at work: what we can see from bone
biopsies.
Pediatr Nephrol. 2006;21:457-462.
[PubMed: 16520951]
43. Specker L, Schonau E. Quantitative bone analysis in children:
current methods and recommendations.
J Pediatr.
2005;146:726-731.
[PubMed: 15973307]
44. Miller PD, Leonard MB. Clinical use of bone mass measurements
in children and adults for the assessment and management of osteoporosis.
In Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:150-161.
45 AJ, Bachrach LK, Fung EB. Bone Densitometry in Growing
Patients. Guidelines for Clinical Practice. Totowa, NJ:
Humana Press; 2007:1-226.
46. Gordon CM, Baim S, Bianchi CL, et al. Special report on
the 2007 Pediatric Position Development Conference of the International
Society for Clinical Densitometry.
South Med Assn.
2008;101:740-743.
[PubMed: 18580718]
47. Brismar TB, Lindgren A-C, Ringertz H, et al. Total bone
mineral measurements in children with Prader-Willi syndrome: the
influence of the skull’s bone mineral content per area
(BMA) and of height.
Pediatr Radiol. 1998;28:38-42.
[PubMed: 9426271]
48. Rauch F, Schonau E. Peripheral quantitative computed tomography
of the distal radius in young subjects—new reference data
and interpretation of results.
J Musculoskeletal Neuronal
Interact. 2005;5:119-126.
[PubMed: 15951627]
49. Wren TALH, Liu X, Pitukcheewanont P, Gilsanz V. Bone densitometry
in pediatric patients: discrepancies in the diagnosis of osteoporosis
by DXA and CT.
J Pediatr. 2005;146:776-779.
[PubMed: 15973317]
50. Zadik Z, Price D, Diamond G. Pediatric reference curves
for multi-site quantitative ultrasound and its modulators.
Osteoporos
Int. 2003;14:857-862.
[PubMed: 12915957]
51. Carpenter TO. Neonatal hypocalcemia. In Favus MJ, ed. Primer
on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.
6th ed. Washington, DC: American Society for Bone and Mineral Research;
2006:224-227.
52. Robertson WC. Calcium carbonate consumption during pregnancy:
an unusual cause of neonatal hypocalcemia.
J Child Neurol.
2002;17:853-855.
[PubMed: 12585729]
53. Holick MF. Vitamin D deficiency. N Engl J Med.
2007;457:266-281.
54. Domico MB, Huynh V, Anand SK, Mink R. Severe hyperphosphatemia
and hypocalcemic tetany after oral laxative administration in a
3-month-old infant. Pediatrics. 2006;118:1580-1583.
56. Yagi H, Furutani Y, Hamada H, et al. Role of TBX1 in human
del22q11.2 syndrome.
Lancet. 2003;362:1366-1373.
[PubMed: 14585638]
57. Kobrynski LJ, Sullivan KE. Velocardiofacial syndrome, DiGeorge
syndrome: the chromosome 22q11.2 deletion syndromes.
Lancet.
2007;370: 1443-1452.
[PubMed: 17950858]
58. Shooner KA, Rope AF, Hopkin RJ, et al. Genetic analyses
in two extended families with deletion 22q11 syndrome: importance
of extracardiac manifestations.
J Pediatr. 2005;146:382-387.
[PubMed: 15756225]
59. Paylor R, Glaser B, Mupo A, et al. Tbx1 haploinsufficiency
is linked to behavioral disorders in mice and humans: implications
for 22q11 deletion syndrome.
Proc Natl Acad Sci.
2006;103:7729-7734.
[PubMed: 16684884]
60. Shiohara M, Mori T, Mei B, et al. A novel gain-of-function
mutation (F821L) in the transmembrane domain of calcium-sensing
receptor is a cause of severe sporadic hypoparathyroidism.
Eur
J Pediatr. 2004;163:94-98.
[PubMed: 14677060]
61. Mittleman SD, Hendy GN, Fefferman RA, et al. A hypocalcemic
child with a novel activating mutation of the calcium-sensing receptor
gene: successful treatment with recombinant human parathyroid hormone. J
Clin Endocrinol Metab. 2006;91:2474-2479.
62. Sanda S, Schlingmann KP, Newfield RS. Autosomal dominant
hypoparathyroidism with severe hypomagnesemia and hypocalcemia,
successfully treated with recombinant PTH and continuous subcutaneous
magnesium infusion.
J Pediatr Endocrinol Metab.
2008;21:385-391.
[PubMed: 18556971]
63. Thakker RV. Genetics of endocrine and metabolic disorders:
Parathyroid.
Rev Endocrinol Metab Dis. 2004;5:37-51.
[PubMed: 14966388]
64. Pinsker JE, Rogers W, McLean S, et al. Pseudohypoparathyroidism
type 1a with congenital hypothyroidism.
J Pediatr Endocrinol
Metab. 2006;19:1049-1052.
[PubMed: 16995592]
65. Levine MA. Parathyroid hormone resistance syndromes. In
Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:220-224.
66. Sakamoto A, Chen M, Kobayashi T, et al. Chondrocyte-specific
knockout of the G protein G
sα leads to
epiphyseal and growth plate abnormalities and ectopic chondrocyte
formation.
J Bone Miner Res. 2005;20:663-671.
[PubMed: 15765186]
67. Weinstein LS, Liu J, Sakamoto A, et al. Minireview:
GNAS:
normal and abnormal functions.
Endocrinology. 2004;145:5459-5464.
[PubMed: 15331575]
68. Aldred MA. Genetics of pseudohypoparathyroidism types Ia
and Ic.
J Pediatr Endocrinol Metab. 2006;19:635-640.
[PubMed: 16789628]
69. Juppner H, Bastepe M. Different mutations within or upstream
of the
GNAS locus cause distinct forms of pseudohypoparathyroidism.
J
Pediatr Endocrinol Metab. 2006;19:641-646.
[PubMed: 16789629]
70. Mayer A, Ploix C, Orgiazzi J, et al. Calcium-sensing receptor
antibodies are relevant markers of acquired hypoparathyroidism.
J
Clin Endocrinol Metab. 2004;89:4484-4488.
[PubMed: 15356052]
71. Gavalas NG, Kemp EH, Krohn KJE, et al. The calcium-sensing
receptor is a target of autoantibodies in patients with autoimmune
polyendocrine syndrome type 1.
J Clin Endocrinol Metab.
2007;92:2107-2114.
[PubMed: 17374709]
72. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes.
N
Engl J Med. 2004;350:2068-2079.
[PubMed: 15141045]
73. Perheentupa J. Autoimmune polyendocrinopathy-candidasis-ectodermal
dystrophy.
J Clin Endocrinol Metab. 2006;91:2843-2850.
[PubMed: 16684821]
74. Mathis D, Benoist C. A decade of AIRE.
Nature Rev/Immunol.
2007;7:645-650.
[PubMed: 17641664]
75. Kyewski B. A breath of Aire in the periphery.
Science.
2008;321:776-777.
[PubMed: 18687943]
76. Goltzman D, Cole DEC. Hypoparathyroidism. In Favus MJ, ed. Primer
on the Metabolic Bone Diseases and Disorders of Mineral Metabolism.
6th ed. Washington, DC: American Society for Bone and Mineral Research;
2006:216-219.
77. Thakker RV. Hypocalcemia: pathogenesis, differential diagnosis,
and management. In Favus MJ, ed. Primer on the Metabolic
Bone Diseases and Disorders of Mineral Metabolism. 6th
ed. Washington, DC: American Society for Bone and Mineral Research;
2006: 213-215.
78. Downs RW Jr. Miscellaneous causes of hypocalcemia. In Favus
MJ, ed. Primer on the Metabolic Bone Diseases and Disorders
of Mineral Metabolism. 6th ed. Washington, DC: American
Society for Bone and Mineral Research; 2006:227-229.
79. Bradley TJ, Metzger DL, Sanatani S. Long on QT and low on
calcium.
Cardiol Young. 2004;14:667-670.
[PubMed: 15680004]
80. Winer KK, Sinail N, Peterson D, et al. Effects of once versus
twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism.
J
Clin Endocrinol Metab. 2008;93:3389-3395.
[PubMed: 18492754]
81. Langman CB. Hypercalcemic syndromes in infants and children.
In Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:209-212.
82. Shane E, Irani D. Hypercalcemia: pathogenesis, clinical
manifestations, differential diagnosis, and management. In Favus
MJ, ed. Primer on the Metabolic Bone Diseases and Disorders
of Mineral Metabolism. 6th ed. Washington, DC: American
Society for Bone and Mineral Research; 2006:176-180.
83. Marx SJ. Familial hypocalciuric hypercalcemia. In Favus
MJ, ed. Primer on the Metabolic Bone Diseases and Disorders
of Mineral Metabolism. 6th ed. Washington, DC: American
Society for Bone and Mineral Research; 2006:188-190.
84. Brown EM. Editorial: mutant extracellular calcium-sensing
receptors and severity of disease.
J Clin Endocrinol Metab.
2005;90:1246-1248.
[PubMed: 15699544]
85. Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular
pathways, and syndromes.
Endocr Rev. 2005;26:615-661.
[PubMed: 15632315]
86. Bilezikian JP, Silverberg SJ. Primary hyperparathyroidism.
In Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:181-185.
87. Stratakis CA, Ball DW. A concise genetic and clinical guide
to multiple endocrine neoplasias and related syndromes.
J
Pediatr Endocrinol Metab. 2000;13:457-465.
[PubMed: 10803862]
88. Cesur Y, Caksen H, Fundem A, et al. Comparison of low and
high dose of vitamin D treatment in nutritional vitamin D deficiency
rickets.
J Pediatr Endocrinol Metab. 2003;16:1105-1109.
[PubMed: 14594170]
89. Chan W, Sheehan S, Miller LC, Sadeghi-Najad A. Hypercalcemia
in a newly arrived international adoptee.
J Pediatr Endocrinol
Metab. 2006;19:1249-1250.
[PubMed: 17172086]
90. Kawaguchi M, Mitsuhashi Y, Kondo S. Iatrogenic hypercalcemia
due to vitamin D3 ointment (1,24(OH)2D3) combined with thiazide
diuretics in a case of psoriasis.
J Dermatol. 2003;30:801-804.
[PubMed: 14684937]
91. Adams JS, Hewison M. Hypercalcemia caused by granuloma-forming
disorders. In Favus MJ, ed. Primer on the Metabolic Bone
Diseases and Disorders of Mineral Metabolism. 6th ed. Washington,
DC: American Society for Bone and Mineral Research; 2006:200-202.
92. Jacobs TP, Bilezikian JP. Clinical review: rare causes of
hypercalcemia.
J Clin Endocrinol Metab. 2005;90:6316-6322.
[PubMed: 16131579]
93. Wysolmerski JJ. Miscellaneous causes of hypercalcemia. In
Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:203-208.
94. Gabriely I, Leu JP, Barzel US. Back to basics.
N
Engl J Med. 2008;358:1952-1956.
[PubMed: 18450607]
95. Prince RL. Secondary and tertiary hyperparathyroidism. In
Favus MJ, ed. Primer on the Metabolic Bone Diseases and
Disorders of Mineral Metabolism. 6th ed. Washington, DC:
American Society for Bone and Mineral Research; 2006:190-195.
96. Khan N, Licata A, Rogers D. Intravenous bisphosphonate for
hypercalcemia accompanying subcutaneous fat necrosis: a novel treatment
approach.
Clin Pediatr. 2001;40:217-219.
[PubMed: 11336421]
97 Schlingmann KP, Waldegger S, Konrad M, et al. TRPM6 and TRPM7—Gatekeepers
of human magnesium metabolism. Biochim Biophys Acta.
2007;1772:813-821.
98. Kollars J, Zarroug AE, van Heerden J, et al. Primary hyperparathyroidism
in pediatric patients.
Pediatrics. 2005;115:974-980.
[PubMed: 15805373]
99. Bornemann M. Management of primary hyperparathyroidism in
children.
South Med J. 1998;91:475-476.
[PubMed: 9598859]
100. Ix JH, Quarles LD, Chertow GM. Guidelines for disorders
of mineral metabolism and secondary hyperparathyroidism should not
be modified.
Nat Clin Pract Nephrol. 2006;2:337-339.
[PubMed: 16932455]